TCF20 and neoplasm: Previous studies have shown that treatment of xenograft tumors with an AR-1–deficient STm strain could force tumor cells from G0/G1 to S/G2/M phase, sensitizing the tumor to chemotherapy with combined methioninase therapy (73, 74), thus also demonstrating a way by which STm treatment directly affects tumor cells.